EGFR and colorectal carcinoma: Hence, GFHPD or anti-EGFR antibody therapy associated reduction in colonic OXPHOS activity but improved goblet cell differentiation points to metabolic reprogramming of colorectal carcinomas towards a low-energetic balanced metabolism, thereby preventing cell proliferation and CRC tumor progression.